CoChat

Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections

Starr, Matthew R., Kung, Felix F., Mejia, Camilo A., Bui, Yvonne T., Bakri, Sophie J. · 2020 · Retina

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Abstract

Purpose: To identify the visual acuity outcomes of patients with age-related macular degeneration treated with intravitreal anti–vascular endothelial growth factor injections over a 10-year period. Methods: This was a retrospective, cohort study of eyes with exudative age-related macular degeneration that received ≥2 intravitreal anti–vascular endothelial growth factor injections and had at least 10 years of follow-up after the initiation of treatment. Snellen visual acuity was recorded at baseline and then annually until the last year of follow-up. Optical coherence tomography data were collected at the time of treatment initiation and at the last examination visit. A subanalysis was performed on patients who continued to receive anti–vascular endothelial growth factor therapy using a modified treat and extend protocol versus those who discontinued treatment for longer than 1 year. Results: One hundred thirty eyes of 115 patients met the inclusion criteria. The mean follow-up after treatment initiation was 11.1 ± 0.7 years. Eyes received an average of 45.1 ± 32.3 intravitreal injections in total and a mean of 5 to 7 injections per year. The baseline mean logMAR visual acuity was 0.61 ± 0.5 (Snellen acuity 20/81), and the final mean logMAR visual acuity was 0.88 ± 0.7 (20/152, P value = <0.0001). There were 40 eyes that received at least one injection every year. These eyes did not have a significant change in visual acuity between the baseline and final examinations 0.47 ± 0.4 (20/59 vs. 0.58 ± 0.5 [20/76, P = 0.28]), whereas the eyes that did not receive at least one injection every year saw a significant decline in visual acuity 0.67 ± 0.5 (20/94 vs. 1.01 ± 0.7 [20/205, P < 0.0001]). Conclusion: Eyes with exudative age-related macular degeneration that received intravitreal injections every year had stable visual acuity over a 10-year period. Continuous intravitreal anti–vascular endothelial growth factor therapy may stabilize visual acuity for 10 years and potentially longer.

Overview

Integrity signals

Registry

Crossref · 10.1097/iae.0000000000002668

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

See all 22

Metadata

Authors
Starr, M. R., Kung, F. F., Mejia, C. A., Bui, Y. T., & Bakri, S. J.
Affiliations
  • Mayo Clinic (US)
  • Mayo Clinic Alix School of Medicine, Rochester, Minnesota.
Corresponding author
  • Starr, Matthew R.
  • Bakri, Sophie J.
Venue
Retina
Published
2019-11-13
Volume
40
Issue
9
Pages
1665-1672
ISSN
0275-004X (ISSN-L)
OpenAlex
W2985629677
Cited by
22
References
33
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 6 · 2020: 5
FWCI
3.43
Type
journal article
Language
en
Open access
closed
Locations
  • Retina (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
neovascular age-related macular degeneration, intravitreal anti-VEGF injection, visual acuity outcomes, long-term follow-up, treat-and-extend protocol, treatment discontinuation, visual acuity stability, anti-VEGF therapy, optical coherence tomography, retinal pigment epithelium thickness, retinal thickness, retinal pigment epithelium
MeSH terms
Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Exudates and Transudates, Female, Follow-Up Studies, Humans, Male, Retrospective Studies, Visual Acuity, Treatment Outcome, Choroidal Neovascularization, Angiogenesis Inhibitors, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections. https://app.cochat.ai/papers/10.1097/iae.0000000000002668
The paper
Starr, M. R., Kung, F. F., Mejia, C. A., Bui, Y. T., & Bakri, S. J. (2020). Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections. Retina. https://doi.org/10.1097/iae.0000000000002668

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.